-
Mashup Score: 4A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy - 9 month(s) ago
Boulch et al. report that CD4+ CAR T cells play a more important role than their CD8+ counterparts in triggering cytokine release syndrome, a life-threatening complication of CAR T cell therapy. Fine-tuning of the CD4:CD8 CAR T cell ratio may therefore help mitigate CAR T cell-associated toxicities.
Source: www.cell.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 15
The FDA approved Lantidra, the first cellular therapy for the treatment of adults with type 1 diabetes.
Categories: Cardiologists, Latest HeadlinesTweet-
RT @FDAMedia: FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes https://t.co/tR3GgKnbbu
-
-
Mashup Score: 0Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma - 1 year(s) ago
Key Points. Mosunetuzumab is active as a single agent and yields complete responses in 24% of heavily pretreated patients with R/R DLBCL.Step-up dosing mitigate
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet-
Mosunetuzumab in r/r DLBCL 88pts (DLBCL 74%, tFL 26%) CR 24%, ORR 42%, medianTTR 1.4mo, mDOR 7mo, medianTT CR 3mo mPFS 3.2mo, mOS 11.5mo Prior CAR-T: 26/88 w CR 12% CRS 26% (mainly Gr 1-2) Small n w bulky dx...#lymsm Kudos to @nancybartlettMD & team https://t.co/FnO96QnxyI
-
-
Mashup Score: 55-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1) - 1 year(s) ago
Key Points. Axicabtagene ciloleucel induced long-term survival with no new safety signals in patients with refractory large B-cell lymphomaDurable responses wer
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet-
5yr FU Supports Curative Potential of Axi-Cel in R/R LBCL (ZUMA-1) Median FU of 63.1 mo Median EFS - 5.7 mo 5yr EFS - 30.3% Ongoing response in 31% of pts Median OS - 25.8 mo 5-year OS - 42.6% Early CAR T-cell expansion associated with ongoing response https://t.co/ZYcXpF2Zj8
-
-
Mashup Score: 3Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas - 1 year(s) ago
Sworder et al. develop and apply a tool to simultaneously profile tumor and effector-mediated determinants of resistance to anti-CD19 CAR T cells using cell-free DNA. The authors profile two independent cohorts of patients with relapsed/refractory large B cell lymphoma and identify genomic alterations, molecular thresholds, and microenvironmental changes associated with resistance.
Source: Cancer CellCategories: Cardiologists, Latest HeadlinesTweet-
Very elegant work with actionable insights regarding resistance to anti-CD19 CAR-T for LBCL!👏👏 https://t.co/21xbIUPJjV https://t.co/N9AzHGvItZ
-
-
Mashup Score: 0CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19 - 1 year(s) ago
Chimeric antigen receptors (CARs) are synthetic engineered receptors with an antigen recognition domain derived from a high-specificity monoclonal antibody that can target surface molecules on tumor cells. T cells are genetically engineered to express CARs, thereby harnessing the antigen-recognition ability of antibodies and effector function of T cells. Target surface molecule selection is…
Categories: Cardiologists, Latest HeadlinesTweet-
Very nice review! 👏🏽👏🏽 CAR-T for B-cell lymphomas with a focus on targets beyond CD19 #CARTcell #lymsm #TcellRx #celltherapy https://t.co/ecbcpXHbIQ https://t.co/vXMj5ebQwX
-
-
Mashup Score: 0
Original Article from The New England Journal of Medicine — Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Source: New England Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet-
Glofitamab for r/r DLBCL N=154 Med fu of 12.6mo CR 39% in total population CR 35% (prior CART) Median time to a CR 42 days 78% ongoing CR at 12mo Gr >=3CRS 4% Gr >=3 neurotox 3% #ASHkudos to @mike_dickinson1 #ASH22 #lysm https://t.co/2iN83AXW6n
-
-
Mashup Score: 0Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function - 1 year(s) ago
Key Points. Bispecific CAR T cells circumvent outgrowth of antigen negative tumor cells in vivoTandem and bicistronic CARs have reduced sensitivity for single a
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet-
Targeting multiple antigens over monospecific CARs may not be a "one size fits all" #lymsm #CART Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function https://t.co/SNDuJrJX26
-
-
Mashup Score: 3Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy - 2 year(s) ago
AbstractA major complication of chimeric antigen receptor (CAR) T-cell therapy is immune effector cell–associated neurotoxicity syndrome (ICANS), which presents as aphasia, confusion, weakness, somnolence, seizures, and coma. This is similar to the neurologic manifestations of hypophosphatemia, which can result from sudden increases in metabolic demand for phosphorylated intermediates (e.g.,…
Categories: Cardiologists, Latest HeadlinesTweet-
In vitro CAR T-cell activity associated with ⬆️consumption of extracellular phosphorus Correlation between ⬇️serum phosphorus levels & incidence of ICANS in 77pts Important implications for monitoring of CARTOX #lymphoma #CARTx https://t.co/dfJDmmDiGF
-
-
Mashup Score: 1Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer - 2 year(s) ago
Chromosomal alteration of BCL-2 leads to poorer outcomes in patients with lymphoma after anti-CD19 CART therapy, but combination of anti-CD19 CART cells overexpressing a BCL-2 mutant with venetoclax leads to synergistic antitumor effects.
Categories: Cardiologists, Latest HeadlinesTweet-
BCL2 alteration a poor prognostic factor post CART In vivo synergy with CD19 CART+VEN in VEN-sensitive NHL VEN+CART➡️toxic to CART cells Synergy in vivo:⬆️cytotoxicity ⬆️CART survival with engineered VEN-resistant CART+VEN 👏👏 @MarcoRuella and team! https://t.co/lL8c19wwLr
-
RT @MaxMamonkin: CD4+ CART are a driver of CRS in high tumor burden scenarios. https://t.co/LbamddCMnH